Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate

Nuclear Medicine and Biology

Volumn 24, Issue 3, 1997, Pages 255-261

  Zalutsky, Michael R ^a   Stabin, Michael G ^b   Larsen, Roy H ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

Author keywords

Astatine 211; Dosimetry; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; ASTATINE 211; IODINE 131; IODOBENZOIC ACID DERIVATIVE; MONOCLONAL ANTIBODY I 131; N SUCCINIMIDYL 3 ASTATOBENZOATE AT 211; N SUCCINIMIDYL 3 IODOBENZOATE I 131; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; DOSIMETRY; DRUG CONJUGATION; DRUG DISTRIBUTION; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIATION DOSE; RADIOIODINATION; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; GLIOMA; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; IODINE RADIOISOTOPES; MICE; NEOPLASM TRANSPLANTATION; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030844622     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00060-7     Document Type: Article

References (49)

1. Barendsen G. W., Beusker T. L. J., Vergroesen A. J. and Budke L. (1960) Effects of different radiations on human cells in tissue culture II: Biological experiments. Radiat. Res. 13, 841-849.
2. 2 - A preliminary report. J. Neurooncol. 24, 109-122.
3. Bourdon M. A., Wikstrand C. J., Furthmayr H., Matthews T. J. and Bigner D. D. (1983) Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43, 2796-2805.
4. 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin. Cancer Res. 2, 963-972.
5. Cristy M. and Eckerman K. (1993) SEECAL: Program to calculate age-dependent specific effective energies. ORNL/TM-12351, Oak Ridge National Laboratory, Oak Ridge, TN.
6. Evans J., Stabin M. and Stubbs M. (1995) Specific absorbed fractions of energy from internal photon sources in brain tumor and cerebrospinal fluid. Med. Phys. 22(3), 331-340.
7. Fuchs H. E., Archer G. E., Colvin O. M., Bigner S. H., Schuster J. M., Fuller G. N., Muhlbaier L. H., Schold S. C., Jr., Friedman H. S. and Bigner D. D. (1990) Activity of intrathecal 4-hydroperoxy-cyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res. 50, 1954-1959.
8. Garg P. K., Bigner D. D. and Zalutsky M. R. (1991) Tumor dose enhancement via improved antibody radiohalogenation. In: Monoclonal Antibodies - Applications in Clinical Oncology, (Edited by Epenetos AA), pp. 103-114. Chapman and Hall, London.
9. 2 fragment. Cancer Res. 50, 3514-3520.
10. 125I]iodobenzoyl conjugate. Bioconjugate Chem. 2, 171-179.
11. Hall E. J. (1988) Radiobiology for the Radiologist, 3rd edn., pp. 161-177. Lippincott, Philadelphia.
12. He X., Archer G. E., Wikstrand C. J., Morrison S. L., Zalutsky M. R., Bigner D. D. and Batra S. K. (1994) Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J. Neuroimmunol. 52, 127-137.
13. Howeedy A. A., Virtanen I., Laitinen L., Gould N. S., Koukoulis G. K. and Gould V. E. (1990) Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab. Invest. 63, 798-806.
14. Howell R. W., Azure M. T., Narra V. R. and Rao D. V. (1994) Relative biological efectiveness of alpha-particle emitters in vivo at low doses. Radiat. Res. 137, 352-360.
15. Huneke R. B., Pippin C. G., Squire R. A., Brechbiel M. W., Gansow O. A. and Strand M. (1992) Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 52, 5818-5820.
16. Humm J. L., Roeske J. C., Fisher D. R. and Chen G. T. Y. (1993) Microdosimetric concepts in radioimmunotherapy. Med. Phys. 20, 535-541.
17. International Commission on Radiological Protection (1991) 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Pergamon Press, New York.
18. International Commission on Radiological Protection (1979) Limits for Intakes of Radionuclides by Workers. ICRP Publication 30m, Part 1. Pergamon Press, Oxford.
19. 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl. Med. Biol. 22, 45-54.
20. Juweid M., Sharkey R. M., Markowitz A., Behr T., Swayne L. C., Dunn R., Hansen H. J., Shevitz J., Leung S.-O., Rubin A. D., Herskovic T., Hanley D. and Goldenberg D. M. (1995) Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. (Suppl.) 55, 5899-5907.
21. Kassis A. I., Harris C. R., Adelstein S. J., Ruth T. J., Lambrecht R. and Wolf A. P. (1986) The in vitro radiobiology of astatine-211 decay. Radiat. Res. 105, 27-36.
22. 131I-19-iodocholesterol: The pitfalls of using tissue concentration data," by M. Blau. J. Nucl. Med. 16, 248-249.
23. Kozak R. W., Atcher R. W., Gansow O. A., Friedman A. M., Hines J. J. and Waldman T. A. (1986) Bismuth-212-labeled anti-Tac monoclonal antibody: α-Particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. (USA) 83, 474-478.
24. 125I-labelled monoclonal antibodies: Biodistribution in mice carrying human osteosarcoma xenografts. J. Label. Compd. Radiopharm. 34, 773-785.
25. 211At reaction. Appl. Radiat. Isotop. 47, 135-143.
26. Loevinger R., Budinger T. and Watson E. (1991) MIRD Primer for Absorbed Dose Calculations. Society of Nuclear Medicine, New York.
27. Lücke-Huhle C. (1982) Alpha-irradiation-induced G2 delay: A period of cell recovery. Radiat. Res. 89, 298-308.
28. Macklis R. M., Kinsey B. M., Kassis A. I., Ferrara J. L. M., Atcher R. W., Hines J. J., Coleman C. N., Adelstein S. J. and Burakoff S. J. (1988) Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 240, 1024-1026.
29. Meek J. L. and Neff N. H. (1973) Is cerebrospinal fluid the major avenue for the removal of 5-hydroxyindoleacetic acid from the brain? Neuropharmacology 12, 497-499.
30. Moseley R. P., Papanastassiou V., Zalutsky M. R., Ashpole R. D., Evans S., Bigner D. D. and Kemshead J. T. (1992) Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int. J. Cancer 52, 38-43.
31. Murphy-Ullrich J. E., Lightner V. A., Aukhil I., Yan Y. Z., Erickson H. P. and Höök M. (1991) Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J. Cell Biol. 115, 1127-1136.
32. 212Bi alpha-particle irradiation. Nucl. Med. Biol. 20, 795-805.
33. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B., Matthews D. C., Fisher L. D. and Bernstein I. D. (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329, 1219-1224.
34. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res. (Suppl.) 55, 5916-5920.
35. Roeske J. C. and Chen G. T. Y. (1991) A dosimetry model for intracavitary radioimmunotherapy of cystic brain tumors. Antibody Immunoconjugates Radiopharm. 4, 657-647.
36. Roeske J. C., Chen G. T. Y., Atcher R. W., Pelizzari C. A., Rotmensch J., Haraf D., Montag A. and Weichselbaum R. R. (1990) Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int. J. Radiat. Oncol. Biol. Phys. 19, 1539-1548.
37. Roeske J. C. and Stinchcomb T. C. (1996) A clinical dosimetry system for therapeutic alpha-particle emitters. Department of Energy Workshop on Alpha-Particle Emitters, Denver, Colorado, June 1996.
38. Schuld S. C., Bullard D. E., Bigner S. H., Jones T. R. and Bigner D. D. (1983) Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice. J. Neurooncol. 1, 5-14.
39. Staben, M. (1996) MIRDOSE - the personal computer software for use in internal dose assessment in nuclear medicine. J. Nucl. Med. 37, 538-546.
40. Sullivan M., Hackett P., George L. and Thompson R. (1960) Irradiation ot the intestine by radioisotopes. Radiat. Res. 13, 343-355.
41. Tjandra J. J., Ramadi L. and McKenzie I. F. (1990) Development of human anti-murine antibody (HAMA) response in patients. Immunol. Cell Biol. 68, 367-576.
42. Turkington T. G., Zalutsky M. R., Jaszczak R. J., Garg P., Vaidyanathan G. and Coleman R. E. (1993) Measuring astatine-211 distributions with SPECT. Phys. Med. Biol. 38, 1121-1130.
43. Weber D. A., Eckerman K. F., Dillman L. T. and Ryman J. C. (1989) MIRD: Radionuclide Data and Decay Schemes, pp. 414-415. Society of Nuclear Medicine, New York.
44. 2. Nucl. Med. Biol. 20, 917-927.
45. Zalutsky M. R., Archer G. E., Garg P. K., Batra S. K. and Bigner D. D. (1996) Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parent. Nucl. Med. Biol. 23, 449-458.
46. Zalutsky M. R. and Bigner D. D. (1996) Radioimmunotherapy with α-particle emitting radioimmunoconjugates. Acta Oncologica 35, 373-379.
47. 2 fragments with the alpha particle emitting nuclide astatine211: Preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl. Acad. Sci. (USA) 86, 7149-7153.
48. Zalutsky M. R., McLendon R. E., Garg P. K., Archer G. E., Schuster J. M. and Bigner D. D. (1994) Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res. 54, 4719-4725.
49. Zalutsky M. R., Schuster J. M., Garg P. K., Archer G. E., Dewhirst M. W. and Bigner D. D. (1996) Two approaches for enhancing radioimmunotherapy: Alpha emitters and hyperthermia. In: Recent Results in Cancer Research: Systemic Radiotherapy with Monoclonal Antibodies, (Edited by Sautter-Bihl M-L, Bihl H and Wannenmacher M.), pp. 101-122. Springer, Berlin.